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RESUMO.- [Um mutante gE-negativo de herpesvírus bovino
tipo 1.2a é atenuado para bovinos e induz proteção frente
ao desafio com vírus de campo.] Em estudo prévio os autores
reportaram a construção de um mutante do Vírus da
Rinotraqueíte Infecciosa Bovina (IBR) ou Herpesvírus Bovino tipo
1.2a  (BHV-1.2a),  do qual foi  deletado o  gene que codifica a
glicoproteina E. Esse mutante (265gE-) foi construído a partir de
uma amostra autóctone do vírus, tendo como objetivo seu uso
como amostra vacinal em vacinas diferenciais, capazes de  per-
mitir a diferenciação entre animais vacinados e infectados com
vírus de campo. Para determinar a atenuação e eficácia do 265gE-
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The authors previously reported the  construction of a  glycoprotein E-deleted (gE-) mutant
of  bovine herpesvirus type 1.2a (BHV-1.2a). This mutant, 265gE-, was designed as a vaccinal
strain for  differential vaccines, allowing the distinction  between vaccinated and naturally
infected cattle. In order to determine the safety and efficacy of this candidate vaccine virus,  a
group of calves was inoculated  with  265gE-.  The virus was detected in secretions of inoculated
calves to lower titres and for a shorter period than the parental virus inoculated in control
calves. Twenty one days after inoculation, the  calves were challenged with the wild type
parental virus. Only mild signs of infection were detected on vaccinated calves, whereas  non-
vaccinated controls displayed  intense rhinotracheitis and shed virus for longer and to higher
titres than  vaccinated calves. Six months after vaccination, both vaccinated and control groups
were subjected to reactivation of potentially latent virus.  The mutant 265gE- could  not be
reactivated from vaccinated calves. The clinical signs observed, following the reactivation of
the parental  virus, were again much milder on vaccinated than on non-vaccinated calves.
Moreover, parental virus shedding was considerably reduced on vaccinated calves at
reactivation. In view of its  attenuation, immunogenicity and protective effect upon challenge
and reactivation with a virulent BHV-1, the mutant 265gE- was shown to be suitable for use as
a BHV-1 differential vaccine virus.
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como imunógeno, bezerros foram inoculados por via intranasal
com 106,9 DICC50  do mesmo. O vírus  foi detectado em secre-
ções dos animais inoculados em títulos mais baixos e por um
período mais curto do que  a amostra virulenta parental,  inocu-
lada em animais  controle. Vinte e um dias após, os animais
inoculados com o vírus mutante foram desafiados  com a amos-
tra parental, apresentando somente sinais leves de infecção. Os
animais controle apresentaram intensa  rinotraqueíte e
excretaram  vírus  em títulos mais elevados e por mais tempo do
que os vacinados. Seis meses após a vacinação, foi examinada a
capacidade de reativação da infecção nos bezerros, através da
administração de corticosteróides. O mutante 265gE- não foi
reativado dos animais vacinados. Os sinais clínicos conseqüen-
tes à reativação do vírus parental foram  muito atenuados nos
animais  vacinados, em comparação com os não vacinados. Além
disso, a excreção de vírus de campo foi consideravelmente redu-
zida nestes últimos. Em vista de sua atenuação, imunogenicidade
e efeito protetivo frente ao desafio com uma amostra virulenta
de BHV-1 e subseqüente reativação, o mutante 265gE- demons-
trou apresentar grande potencial para ser utilizado como vírus
vacinal em vacinas diferenciais contra o BHV-1.
TERMOS DE INDEXAÇÃO: BHV-1, IBR, vacina diferencial, gE.
Classificação CNPq: 5.05.02.00-0 Medicina Veterinária Preventiva.
INTRODUCTION
Bovine herpesvirus type 1 (BHV-1), a major pathogen of cattle,
is the agent of infectious bovine rhinotracheitis/infectious
pustular vulvovaginitis  (IBR/IPV). The virus is associated with
a number of other clinical syndromes, including pustular
balanopostitis, conjunctivitis, infertility and abortion (Gibbs
& Rweyemamu 1977). BHV-1 strains have been subdivided
into three distinct genotypes, BHV-1.1, BHV-1.2a and BHV-
1.2b (Metzler et al. 1985). BHV-1.1 and 1.2a seem to be the
most pathogenic, being associated with respiratory disease
and abortion, while BHV-1.2b usually displays  moderate to
low pathogenicity and has not so far been associated to
abortion (Metzler et al. 1985).
The BHV-1 genome encodes several glycoproteins (gps)  that
are expressed on  the viral envelope and membranes of infected
cells.  While some some of these are essential for virus
replication  and mediate  different biological functions
(Rebordosa et al. 1996), other gps are not essential for virus
multiplication, thus representing potential  targets for
deletions aiming  the development of differential vaccines.
Glycoprotein E  (gE),  is one of such non-essential gps
(Mettenleiter et al. 1987, Balan et al. 1994, Dingwell et al. 1994,
Dingwell et al. 1995, Olson & Groose 1997, Dingwell & Jonhson
1998, Maresova et al. 2001). The gE gene  is located in the
unique short (US) region along the BHV-1 genome, consisting
of a 1800 base pair (bp)  fragment  which codes for  a
polypeptide of 575 amino acids (Balan et al. 1994). BHV-1.1 gE-
mutants  reported so far  displayed  reduced pathogenicity in
calves and were excreted for shorter periods than wild type
virus (Van Engelenburg et al. 1994, Chowdhury et al. 1999).  In
view of those findings, such  mutants have been chosen  for
the development of differential BHV-1 vaccines  (Van
Engelenburg et al. 1994, Chowdhury et al. 1999). As the  mutant
viruses do not express gE, vaccinated animals do not  develop
antibodies to this protein, thus, making it possible to
differentiate the immune responses of  naturally infected from
vaccinated animals with serological tests based on the detection
of gE antibodies.
The  differential BHV-1 vaccines available to date have been
prepared with BHV-1.1 strains, the most common subtype
associated with IBR and abortions in Europe and North
America (Metzler et al. 1985).  In Brazil, such vaccines have
not become available yet. In addition,  the differential vaccine
viruses prepared in  the northern hemisfere (Kaashoek et al.
1994, Chowdhury et al. 1999) have not   been tested to deter-
mine their protective potential against viruses circulating
within Brazil, where most BHV-1 isolates  examined so far are
of the 1.2a  genotype (Souza et al. 2002).
Focusing on  the development of a differential vaccine
virus  to be used within the country,  a gE- BHV-1.2a  mutant
virus was constructed  from an autochtonous virus  (Franco
et al. 2001). In the present study, the in vivo behaviour of
such mutant was examined in experimentally inoculated
calves, in order to determine its  attenuation and its  potential
use as  a differential BHV-1 vaccine.
MATERIAL AND METHODS
Experimental design
A group of  four calves  was inoculated with the mutant virus
265gE-. These will   be referred to as  “vaccinated” calves.  A group of
three calves was kept as non-vaccinated controls. Twenty one days
after vaccination, vaccinated and control calves were challenged with
the parental (wild type) virus by intranasal inoculation and monitored
for fourteen days. Six months later, all calves under study were
subjected to dexamethasone administration in attempting to
reactivate latent viruses.
Cells and viruses
The wildtype BHV-1 strain SV265 (SV265 wt) was  isolated from a
heifer  with signs of respiratory infection in São Borja county, Rio
Grande do Sul, Brazil. The virus was used for the construction of  the
mutant virus (265gE-) as described previously  (Franco et al. 2001).
Madin Darby  bovine kidney (MDBK) cells were maintained   in Eagle’s
minimal essential medium (EMEM) supplemented with 5 % to 10 %
fetal bovine serum (FBS, Nutricell), 2 mM glutamine and antibiotics
(100 IU/ml  penicillin and 100 mg/ml streptomycin).
Animal inoculation
Four calves of  mixed European breeds,   three to four months
old, seronegative to BHV-1 and BHV-5,   were  inoculated (vaccinated)
with 106.9 fifty  percent tissue culture infective doses (TCID50) of  the
265gE- mutant, in 2 mL of virus suspension, administered  intranasally
into  the right nostril. Three   calves were kept as non-vaccinated
controls for subsequent challenge. Three additional calves were kept
as non-vaccinated, non-challenged controls throughout.  Clinical signs
and virus specimens were collected as described below.  Twenty one
days later, vaccinated and non-vaccinated calves were challenged
with 109 TCID50 of SV265wt, in  5 mL of suspension administered
intranasally, 2.5 mL  into each  nostril.  Six months after challenge,
all calves were subjected to corticosteroid administration to
reactivate the latent infection. Dexamethasone  (0.1 mg per kg of
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body weight) was administered intravenously  for 5 consecutive days.
Calves were kept under  observation  and samples collected as below.
Clinical examination
Clinical examinations were  performed  daily from day 12 prior
to vaccination up to day 14-post challenge (pc). The same examination
protocol was followed  after dexamethasone administration. Signs
recorded were rectal temperature, respiratory rate, cough,
congestion of the nasal mucosa, conjunctivitis, ocular and nasal
discharges, lesions on  the nasal and oral mucosa and changes in
behaviour and appetite. The clinical scoring method was adapted
from Collie (1992), with modifications based on our previous
experience with BHV-1 experimental inoculations. Thus,  scores were
determined  by attributing different weights to different signs of
disease. Apathy, anorexia, dyspnoea and alterations at  auscultation
were scored on an arbitrary  scale up to 100. Nasal and ocular
secretions, conjunctivitis, erosions of the nasal mucosae,
enlargement of lymphnodes and  cough were scaled up to 10. Body
temperature (TR) was included in individual scores using the
following formula:
Scored  temperature rate (TR) = 100 X (body temperature –  mean of
calf ’s body temperature on the 12 days before   inoculation)
Mean clinical scores were calculated daily for each group.
Six months later, during reactivation attempts, clinical and
virological examinations were recorded as described  above.  In view
of the aging  of calves,  a new record for standard  body temperatures
was obtained by measuring temperatures for 12 days before
reactivation.
Virological examination
Samples for virological examination were collected on  day 12
prior to  inoculation, day 0 (date of inoculation)  and daily  from
days 1 to 14  post  vaccination (pv), as well as  on days 1 to 14  pc and
post reactivation (pr). Nasal and ocular swabs were eluted in 2 mL of
sample medium (EMEM supplemented with 10 times the usual
concentration of antibiotics and 2 % FBS) for one hour at room
temperature. The samples were vigorously shaken, the swabs
removed, drained, the  medium clarified by low speed centrifugation
and stored at –70 °C. Virus titrations  were performed on  microtitre
plates. Infectious  titres were calculated and expressed as log10 TCID50
per 50 mL of nasal or ocular fluid. Serum samples were collected by
jugular venipuncture on days 0, 7, 14  pv, pc and pr. Sera were tested
in serial twofold dilutions in a  standard  BHV-1 neutralizing  antibody
test against  SV265wt (House & Baker 1971).
Identification of  the recovered virus
To confirm the identity of the viruses recovered from
inoculated calves, an immunoperoxidase monolayer assay (IPMA)  was
used, with   either a monoclonal antibody (Mab) directed to gE  as
primary antibody, or an  anti-BHV-1 Mab that recognizes both
SV265wt and 265gE- (Mab 2G5). The  IPMA followed  essentially the
method  described previously (Souza et al. 2002), using initially the
anti-gE Mab (Kaashoek et al. 1995) followed by an anti-mouse
peroxidase/IgG conjugate. In case uncoloured viral plaques were
observed, a second reaction  was performed with the  Mab 2G5 (Roehe
et al. 1997), following the same protocol.
Statistical analysis
Statistical analysis was performed using the Student t-test or
the analysis of variance (ANOVA) where the least significance
difference for p£0.05 was determined. Comparisons were made daily
within the groups. Statistical analysis was performed with Minitab®
for Windows Release 11.1 (Minitab Inc., State College, PA, USA). The
term “significant” (statistically significant) in the text means p £ 0.05.
RESULTS
Clinical signs and virus shedding after vaccination
Clinical signs after inoculation of the  vaccine virus  were
very mild. Serous nasal discharges were detected from day 2
to 5 pv, especially on the right nostril, where the virus had
been inoculated. Rectal temperatures of vaccinated  calves
did not exceed  39.5°C, except for one calf, which presented
pyrexia (39.8°C) on day 6  pv. The vaccinated calves  shed
virus for up to  8 days in  their nasal secretions The highest
virus titre was recorded in one calf on  day 2 pv (105 TCID50/
50 µl). In ocular secretions, the 265gE- mutant  was only
isolated from  one calf  on day 4 pv.
Clinical signs after challenge
After challenge,  all  non-vaccinated calves developed
severe clinical signs, which included apathy, anorexia, rhinitis,
serous to mucopurulent nasal discharges and serous to
Fig. 1. a) Mean clinical scores attributed to calves  vaccinated (265gE)
and non-vaccinated  (SV265 wt) after challenge with  wild type
virus (SV265 wt);  b) clinical scores after  reactivation.  Black
triangles: wild type virus (SV265 wt); black circles:  mutant  virus
(265gE-);  empty squares: control calves.
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mucous ocular discharges, starting from day 3 pc (Fig. 1).  In
the nostrils, formation of vesicles which tended to coalesce
and eventually gave rise to erosions of the mucosae were
detected. Conjuntivitis, nasal stridor, sneezing and sponta-
neous coughing were also recorded. Enlargement of the
retropharyngeal, submandibular and cervical lymphnodes
were observed from days 7 to 12 pc.  Dyspnoea and tracheal
stridor were detected in all non-vaccinated calves. Pyrexia
(>39.5°C) was also a consistent finding (Fig. 2).
In the vaccinated group, all calves had some serous nasal
discharge and a few small erosions on the nasal mucosae.
Clinical scores on  the vaccinated group were very low,  in
comparison to the non-vaccinated group. Pyrexia was not
observed  on calves from the  vaccinated group.
Both vaccinated and control calves  shed virus in nasal
secretions. However,  the amount of virus shed   by  the group
of vaccinated calves was  reduced to  a maximum of  102
TCID50, whereas on  the non-vaccinated group  virus was
excreted for longer and to higher titres (up to 109 TCID50;
Fig. 3). Non-vaccinated calves shed  virus in  ocular secretions
for  12 days, with peaks of infectious titres  at day 4 post
challenge (104.5 TCID50/50 µl; Fig. 4), whereas  only two of the
vaccinated calves shed SV265wt virus in their ocular
secretions,  albeit intermittently and to low  titres on days 1,
3, 6 and 8 pc.
Clinical signs after reactivation
 Vaccinated calves showed  only very mild clinical signs
at reactivation,  whereas  clearly noticeable  respiratory signs
of disease  were observed in non-vaccinated calves (Fig. 1b).
These signs were less intense than those observed during
acute infection following challenge. However,  one of the non-
vaccinated  calves  died on day 11 after  reactivation. This
calf  had  low titres of virus in the  nasal hornets, trachea,
lung, mediastinic and periportal lymphnodes, liver and spleen
(data not shown). Post mortem examination  of this calf
revealed mild pneumonia and hepatic focal necrosis. In such
lesions, BHV-1 antigen was detected by immunohistoche-
mistry (not shown). Nasal  virus shedding in the  group  of
non-vaccinated calves was detected from day 2 to 9  after
reactivation,  and  to  higher titres than  on   vaccinated
calves (Fig. 3).
Fig. 2. Mean rectal temperatures  (oC): a) after challenge of vaccinated
and non-vaccinated calves with  wild type  virus (SV265 wt);  b)
upon reactivation. Black triangles: wild type virus (SV265 wt);
black circles: mutant virus (265gE-);  empty squares: control
calves.
Fig. 3.  Nasal virus shedding:  a) after challenge of vaccinated and
non-vaccinated calves with  wild type  virus (SV265wt);  b) upon
reactivation.  Infectious virus titres expressed in log10 of 50%
tissue culture infective  doses per 50 ml (TCID50). Black triangles:
wild type virus (SV265wt); black circles:  mutant  virus (265gE-);
empty squares: control uninfected calves.
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In the group of vaccinated calves, reactivation was
followed by a shorter period of virus shedding, which  lasted
three days (from day 4 to 6 pr).  Ocular shedding was detected
from day 5 to 7 pr.  All virus samples  recovered from secretions
obtained from vaccinated calves were confirmed as  SV265wt,
as evidenced  by IPMA with the anti-gE  monoclonal antibody
(Souza et al. 2002). The mutant 265gE- was not recovered
from any of the calves after dexamethasone administration.
The neutralizing antibody profile of calves was similar in
both  vaccinated and non-vaccinated calves (Fig. 5). Differences
in antibody titres were never greater than fourfold between
vaccinated and non-vaccinated animals, either after challenge
or after reactivation.
Analysis of virus shed  during the  experiments
After vaccination, only gE-negative plaques were detected
by IPMA. After challenge, no gE-negative viral plaques were
detected. Following dexamethasone induced reactivation,
only gE-positive viral plaques were recovered from nasal and
ocular samples.
DISCUSSION
The 265gE-  vaccine  virus  candidate evaluated  in the present
study  was shown to  be  attenuated when inoculated
intranasally into   three to four  months old calves.   After
inoculation,  the calves  showed only  very mild clinical signs,
as evidenced by the low clinical scores recorded. The  virus
was excreted in lower titres and for a significantly  shorter
period of time than  the SV265wt virus. Other studies have
also shown  reduction in virulence and  viral excretion with
BHV-1.1 gE- mutants (Kaashoek et al. 1994, Van Engelenburg
et al. 1994,  Kaashoek et al. 1998,  Chowdhury et al. 1999).
Likewise, in the present study, the deletion  of gE from
SV265wt appeared to be responsible for the reduced
pathogenicity of the mutant when inoculated into
seronegative calves,  since  calves at the same age inoculated
Fig. 5. a) Neutralizing antibodies after inoculation  of  gE- virus (265gE)
in calves (day 0)  and challenge (day 21)  with  the wild type virus
SV265wt; b) Neutralizing antibody titres after dexamethasone
administration (180 days after  the initial 265 gE- inoculation).
Black circles: calves inoculated with 265gE-; black triangles: calves
inoculated with SV265wt only. White squares: uninfected control
calves. Titres expressed in log10 of the reciprocal of the
neutralizing antibody titre  (refer to text for methods).
Fig. 4. Ocular virus shedding:   a) after challenge of  vaccinated and
non-vaccinated calves with  wild type  virus (SV265wt);   b) upon
reactivation.  Infectious virus titres expressed in  log10 of   50%
tissue culture infective  doses per 50 ml (TCID50). Black triangles:
wild type virus (SV265wt); black circles:  mutant  virus (265gE-);
empty squares: control calves.
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with  SV265wt  were  severely ill. We have not been able to
detect any other  significant  changes along the genome of
265gE-, except for the absence of the  gE gene (Franco et al.
2001). Thus, it is very likely that the attenuated  phenotype
was a consequence of  the gE deletion.
Challenge of vaccinated  calves with wild type virus gave
rise to  very mild clinical signs of infection, whereas
unvaccinated calves developed severe rhinotracheitis.
Although nasal and ocular virus shedding post challenge could
not be  prevented by the vaccination,  infectious  titres and
the duration of  virus shedding   were significantly reduced
on  vaccinated calves. Both aspects are  significant  for
pathogen eradication and disease control programs (Hage et
al. 1994), as pointed out by others  with similar immunogens
(Kaashoek et al.  1994, Chowdhury et al. 1999).
Clinical sighns and virus shedding  were also greatly
reduced on the group of vaccinated calves after reactivation.
Besides, only the wild type virus was recovered after
reactivation.  Although a  265gE-  latent infection may have
been  present, BHV-1 gE- viruses have been reported not to
reactivate readily (Van Engelenburg et al. 1995).  This has
been regarded as a  contributing factor  to the safety of gE-
vaccines. Moreover, the reduction of wild type virus excretion
in vaccinated animals is also of interest, and probably reflects
a reduced  colonization of the trigeminal ganglia by wild type
virus, as pointed out by  Galeota et al. (1997).
In the present study,  it was  demonstrated that the 265gE-
mutant virus  is  attenuated for calves, induces protection
upon challenge and reactivation with a large infectious dose
of the parental wild type BHV-1.2a. Therefore,  265gE-  behaved
as a suitable candidate for a vaccine virus. Additional
experiments are in progress to further examine its
immunogenic potential  in cattle and  to evaluate its protective
effect  upon challenge, not only against  BHV-1.2a, but also
against other herpesviruses of cattle.
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